Covid-19 Action Plan – 2021 Update
In line with our previous Covid-19 Action Plan, Newcells Biotech has continued to review and invest in measures to reduce the risk to its staff and our wider community from the Covid-19
Improved in vitro renal tubular drug transport modelling to meet regulatory and development cost challenges
The proximal tubule is key due to its role in the excretion and reabsorption of many xenobiotic compounds. Due to the high costs associated with drug discovery and the clinical demand for
Development of a physiologically relevant lung model for understanding SARS-CoV-2 infection
Covid-19 is known to infect the lungs. However, the dynamics of viral infection and replication are poorly understood. Alongside the Liverpool School of Tropical Medicine, we have been working to develop a
Development of functioning in vitro lung assay for modelling Covid-19 infection
Newcells Biotech, experts in induced pluripotent stem cell (iPSC) differentiation and assay construction, have confirmed their human lung epithelium model as an effective platform for modelling SARS-CoV-2 infection and replication. Their work alongside the Liverpool School of Tropical Medicine (LTSM) Centre for Drugs and Diagnostics will be crucial in helping
Newcells Biotech scales up its operations in The Biosphere
Newcells Biotech, a pioneering life-sciences spin-out that applies Human induced Pluripotent Stem Cells (hiPSCs) to develop assays for drug development, have consolidated their two laboratory sites into 500m2 of laboratory and co-located office space in The Biosphere, which forms part of the Newcastle Helix cluster. The purpose-built space in the city centre site
Newcells Biotech testing an in-vitro model of the human lung epithelium for application in the fight against SARS-CoV-2
Internationally renowned company, Newcells Biotech, are using their established expertise in human induced pluripotent stem cell (hiPSC) technology to test their existing model of the human lung epithelium as a platform for
Covid-19 Action Plan – A message to our customers, collaboration partners and colleagues
As we all come to terms with the extraordinary and rapidly changing global situation caused by Covid-19, I would like to update you on the plans we have in place to ensure
Newcells Biotech Win Phase II of CRACK IT Challenge 29: ImmuLiver
Newcells Biotech are excited to announce that they are Phase II contract winners of the NC3Rs-funded CRACK IT Challenge (named ImmuLiver). They have been awarded a further funding to continue development of
Newcells Biotech acquires IP for Retinal Organoids from Newcastle University
Newcells Biotech is pleased to announce the acquisition of intellectual property pertaining to the methodology for the differentiation of three-dimensional retinal organoids from human induced pluripotent stem cells (hiPSCs) from Newcastle University. The acquired technology will add to the growing portfolio of proprietary technologies that Newcells
Dr Frank Armstrong appointed as Non-executive Director
Newcells Biotech is pleased to announce that it has appointed Dr Frank Armstrong to its Board as a Non-executive Director. “Attracting an executive of Frank’s proven track-record and expertise is another significant
Newcells Biotech Win Phase I of CRACK IT Challenge 29: ImmuLiver – Securing £99,711 Funding
Newcells Biotech are one of three Phase I contract winners of a challenge-led competition that funds collaborations between industry, academics and SMEs to solve business and scientific ‘Challenges’. The NC3Rs challenge (named ImmuLiver), sponsored by Sanofi
Leading Drug Transport and Drug Toxicity Expert, Dr Colin Brown joins Newcells Biotech
Newcells Biotech has announced that Dr Colin Brown, one of the world’s leading experts on drug transport and drug toxicity in kidney will join the company as Director of ADMET Technology. The company has also
